Moreover, in cancers such as melanoma, FDA approval of atezolizumab (programmed cell death ligand 1 [PD-L1] inhibitor), cobimetinib (MEK inhibitor), and vemurafenib (BRAF V600E inhibitor) for advanced BRAF V600-mutated melanoma illustrates the value of combining these modalities6. This evidence concerns the gene MAP2K7 and melanoma.